Statera Biopharma announced that the Company intends to enter into a non-binding term sheet with respect to a strategic partnership with Lay Sciences, Inc. to license worldwide manufacturing rights to certain Lay Sciences' IgY products containing avian antibodies as an active ingredient. Under the terms of the proposed agreement, Lay Sciences would receive an upfront payment comprised of both equity and cash and would also have the potential to earn royalties and milestones associated with the development of IgY in gastrointestinal and upper respiratory indications.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | +16.67% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 50.81K | |
+1.77% | 42.86B | |
+45.26% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products